洛伐他汀通过METTL3/HDAC6级联抑制OGD/氯化血红素诱导的脑微血管内皮细胞炎症与铁死亡
本研究以氧糖剥夺联合氯化血红素(OGD/H)刺激人脑微血管内皮细胞建立体外脑出血后细胞损伤模型,评估洛伐他汀的保护作用及METTL3/HDAC6机制。结果显示洛伐他汀改善OGD/H诱导的细胞通透性、活力、迁移、成管和凋亡等障碍,并减轻氧化应激、炎症(肿瘤坏死因子-α、白细胞介素-6)和铁死亡。机制上,METTL3通过m6A修饰稳定HDAC6 mRNA,洛伐他汀下调METTL3进而降低HDAC6,从而减轻细胞损伤。该研究为洛伐他汀的神经保护作用提供体外新证据,但尚属细胞水平机制探索。
要点
- 人脑微血管内皮细胞经氧糖剥夺联合氯化血红素(OGD/H)刺激可模拟脑出血后内皮损伤,洛伐他汀可减轻该损伤。
- 洛伐他汀可减轻OGD/H诱导的氧化应激、炎症(肿瘤坏死因子-α、白细胞介素-6)和铁死亡。
- METTL3通过m6A修饰稳定HDAC6 mRNA,洛伐他汀通过下调METTL3降低HDAC6表达。
- 洛伐他汀的保护作用由METTL3/HDAC6级联介导,为体外细胞实验证据。
- 本研究为细胞水平机制研究,未提供动物或临床剂量与结局数据。
适用人群与场景
- 人脑微血管内皮细胞,经氧糖剥夺联合氯化血红素(OGD/H)刺激建立脑出血后体外细胞损伤模型。
研究设计与关键结果
- 研究类型为体外细胞实验,以人脑微血管内皮细胞为对象,采用氧糖剥夺联合氯化血红素(OGD/H)刺激建立损伤模型,洛伐他汀为干预。
- 洛伐他汀保护脑微血管内皮细胞免受OGD/H诱导的功能障碍,并减轻OGD/H诱导的氧化应激、炎症和铁死亡。
- 机制预测显示洛伐他汀与METTL3存在潜在对接构象,METTL3通过mRNA m6A修饰稳定HDAC6 mRNA。
- 洛伐他汀降低OGD/H刺激的人脑微血管内皮细胞中METTL3和HDAC6水平,并通过下调METTL3降低HDAC6表达。
- 洛伐他汀通过METTL3/HDAC6级联减轻OGD/H诱导的脑微血管内皮细胞损伤、炎症和铁死亡。
证据类型、等级与局限
- 证据类型:体外细胞实验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 本文为体外细胞机制研究,未提供急诊或ICU床旁可直接应用的剂量、给药方案或临床结局数据。
- 作者认为洛伐他汀通过潜在METTL3/HDAC6级联抑制OGD/H诱导的人脑微血管内皮细胞炎症和铁死亡,为其神经保护作用提供新证据。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Intracerebral hemorrhage (ICH) induces dysfunction in brain microvascular endothelial cells (BMVECs), thereby contributing to secondary brain injuries. Emerging evidence implicates methyltransferase-like 3 (METTL3) and histone deacetylase 6 (HDAC6) as critical mediators of inflammation and ferroptosis that contribute to post-ICH neurological impairment. Lovastatin exhibits anti-inflammatory, anti-oxidative, and neuroprotective properties. This study elucidated the therapeutic potential of lovastatin in attenuating BMVEC injury following ICH while investigating the mechanistic involvement of METTL3 and HDAC6 in this protective process.
METHODS: The cell damage model following ICH was generated by stimulating human BMVECs with oxygen and glucose deprivation (OGD) and hemin (OGD/H). Cell impairment was assessed by detecting permeability. Cell viability, migration, tube formation, and apoptosis were evaluated by cell counting kit-8, transwell, tube formation, and flow cytometry analyses, respectively. Tumor necrosis factor-α and interleukin-6 levels were detected by Enzyme-Linked Immunosorbent Assay. Cell ferroptosis was analyzed by assessing related factor expression. Methylated RNA immunoprecipitation, RIP, quantitative PCR, and actinomycin D treatment assays were used to test the METTL3/HDAC6 relationship.
RESULTS: Lovastatin protected BMVECs from OGD/H-evoked dysfunction. Moreover, lovastatin relieved OGD/H-evoked oxidative stress, inflammation, and ferroptosis in BMVECs. Mechanistically, the potential docking poses of lovastatin with METTL3 were predicted, and METTL3 stabilized HDAC6 mRNA through mRNA m6A modification. Lovastatin reduced METTL3 and HDAC6 levels in OGD/H-stimulated human BMVECs, and lovastatin decreased HDAC6 expression by downregulating METTL3. Furthermore, lovastatin alleviated OGD/H-induced BMVEC impairment, inflammation, and ferroptosis by the METTL3/HDAC6 cascade.
CONCLUSION: Our study demonstrates that lovastatin suppresses OGD/H-induced inflammation and ferroptosis in human BMVECs through the potential METTL3/HDAC6 cascade, providing novel evidence for the neuroprotective role of lovastatin.
参考来源
- Wang X, Peng L, Han L, et al. Suppressive Effects of Lovastatin on OGD/HEMIN-INDUCED Inflammation and Ferroptosis in Brain Microvascular Endothelial Cells Through the METTL3/HDAC6 Cascade. Shock. 2025. PMID: 40961409. doi:10.1097/SHK.0000000000002688
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。